Browse All

Current Filters

CLEAR FILTER x

TITLE

Serum Glial Fibrillary Acidic Protein compared with Neurofilament Light Chain as Biomarker for Multiple Sclerosis Disease Progression

Author:Meier, Stephanie   Benkert, Pascal   Maleska Maceski, Aleksandra   Schaedelin, Sabine   Oechtering, Johanna   Melie-Garcia, Lester   Cagol, Alessandro   Barakovic, Muhamed   Galbusera, Riccardo   Achtnichts, Lutz   Lalive, Patrice H.   Bridel, Claire   Müller, Stefanie   Pot, Caroline   Salmen, Anke   Disanto, Giulio   Zecca, Chiara   Abdelhak, Ahmed   Barro, Christian   Thebault, Simon   D’Souza, Marcus   Derfuss, Tobias   Orleth, Annette   Khalil, Michael   Yaldizli, Özguer   Hermesdorf, Marco   Wiendl, Heinz   Piehl, Fredrik   Fischer, Urs   Kappos, Ludwig   Gobbi, Claudio   Granziera, Cristina   Leppert, David   Willemse, Eline A.J.   Kuhle, Jens   

Session Name:P5: MS Prognosis/Epidemiology  

Topic:MS and Inflammatory Disease  

Program Number:P5.016  

Author Institution:Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Translational Imaging in Neurology (ThINK) Basel, Department of Biomedical Engineering  Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland, Allschwill, Basel, Switzerland  Department of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland, Aarau, Switzerland  Department of Clinical Neurosciences, Division of Neurology, Unit of Neuroimmunology, University Hospital of Geneva and Faculty of Medicine, Geneva, Switzerland, Geneva, Switzerland  Department of Neurology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland, St. Gallen, Switzerland  Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland, Lausanne, Switzerland  Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, Bern, Switzerland  Multiple Sclerosis Center (MSC), Department of Neurology, Neurocenter of Southern Switzerland  Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland, Lugano, Switzerland  Weill Institute for Neurosciences, Department of Neurology, University of California at San Francisco (UCSF), San Francisco, California, USA, San Francisco, CA  Department of Neurology, Harvard Medical School, Boston, MA, USA, Boston, MA  Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada, Ottowa, ON, Canada  Department of Neurology, Medical University of Graz, Graz, Austria, Graz, Austria  Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany, Münster, Germany  Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany, Muenster, Germany  Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden  Center for Neurology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Sweden  

Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS

Author:Alvarez, Enrique   Kuhle, Jens   Kappos, Ludwig   Ziemssen, Tjalf   Arnold, Douglas   Cross, Anne   Boer, Ibolya   Das Gupta, Ayan   Hu, Xixi   Kukkaro, Petra   Kieseier, Bernd   Zielman, Ronald   Hauser, Stephen   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.013  

Author Institution:Department of Neurology, Rocky Mountain MS Center at the University of Colorado, Aurora, CO  Neurology, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland  Center of Clinical Neuroscience, Department of Neurology, University Clinic Carl Gustav Carus, Dresden, Germany  McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University and NeuroRx Research, Montreal, QC, Canada  Washington University School of Medicine, Saint Louis, MO  Novartis Pharma AG, Basel, Switzerland  Novartis Healthcare, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma B.V., Amsterdam, Netherlands  UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA